Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | TLR4 | O00206 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8393094 | 0.90 | TP53 (0.39) | CYP1A2TP53ALDH1A1MAPTKMT2A | |
| SCHEMBL5259007 | 0.84 | TP53 (0.47) | CYP1A2TP53ALDH1A1HPGDLMNA | |
| SCHEMBL28863284 | 0.83 | — | — | |
| SCHEMBL1036088 | 0.82 | CYP1A2 (0.46) | CYP1A2TP53ALDH1A1HPGDHSD17B10 | |
| SCHEMBL11861937 | 0.80 | CYP1A2 (0.48) | CYP1A2TP53ALDH1A1HPGDTSHR | |
| SCHEMBL10704088 | 0.80 | CYP1A2 (0.48) | CYP1A2TP53ALDH1A1HPGDTSHR | |
| SCHEMBL28240170 | 0.79 | CYP1A2 (0.31) | CYP1A2TP53ALDH1A1HPGDLMNA | |
| SCHEMBL28009928 | 0.77 | NPC1 (0.33) | — | |
| SCHEMBL4501903 | 0.77 | — | — | |
| SCHEMBL25259165 | 0.74 | MAPT (0.32) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332132-B1 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | UCB PHARMA SA (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-6780874-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIPROLIFERATIVE AGENT | CELLTECH R & D LIMITED (GB) | 2004-08-24 | — | — | US | disclosed |
| US-20030229116-A1 | ENAMINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2003-12-11 | — | — | US | disclosed |
| US-6610700-B2 | Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example | CELLTECH R & D LIMITED (GB) | 2003-08-26 | — | — | US | disclosed |
| EP-1332132-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | Celltech R&D Limited (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-20020037909-A1 | Enamine derivatives | UCB PHARMA S.A. (BE) | 2002-03-28 | — | — | US | disclosed |
| WO-2001079173-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R & D LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| US-4324676-A | CORROSION INHIBITORS FOR COOLANTS OR ANTIFREEZES | THE DOW CHEMICAL COMPANY (US) | 1982-04-13 | — | — | US | disclosed |
| US-4080334-A | Intermediates in the total synthesis employing substituted isoxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 1978-03-21 | — | — | US | disclosed |
| US-4044004-A | Total steroid synthesis employing substituted isoxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-3984428-A | Isoxazolyl-substituted perhydrobenzindenes | HOFFMANN-LA ROCHE INC. (US) | 1976-10-05 | — | — | US | disclosed |
| US-3979458-A | Production of unsaturated carbocyclic ketones | SYNTEX CORPORATION (PM) | 1976-09-07 | — | — | US | disclosed |
| US-3972896-A | Aryl ketals of polycyclic oxo compounds and processes | HOFFMANN-LA ROCHE INC. (US) | 1976-08-03 | — | — | US | disclosed |
| US-3960895-A | Aryl ketals of polycyclic oxo compounds and processes | HOFFMANN-LA ROCHE INC. (US) | 1976-06-01 | — | — | US | disclosed |
| US-3960896-A | Aryl ketals of polycyclic oxo compounds and processes | HOFFMANN-LA ROCHE INC. (US) | 1976-06-01 | — | — | US | disclosed |
| US-3959322-A | Synthesis of 13-alkyl-gon-4-ones | Smith, Herchel (US) | 1976-05-25 | — | — | US | disclosed |
| US-3951958-A | VAGINOTROPIC | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3951959-A | VAGINOTROPIC | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3950358-A | ARYL KETALS OF 3,7-DIHYDROXY-11-OXO-DODEC-1-ENE | HOFFMANN-LA ROCHE INC. (US) | 1976-04-13 | — | — | US | disclosed |
| US-3948951-A | Aryl ketals of 1-chloro-4-oxo-pentane | HOFFMANN-LA ROCHE INC. (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037909-A1 | Enamine derivatives | CCR1, ITGB2, CCR10 | CYP1A2 521/4885TP53 3731/4885ALDH1A1 1142/4885 |
| US-20030229116-A1 | ENAMINE DERIVATIVES | ITGB2, CCR1, CCR10 | CYP1A2 572/4885TP53 3754/4885ALDH1A1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.